The global cardiac rhythm management (CRM) market continues to evolve as arrhythmia care shifts toward minimally invasive ablation, advanced mapping, and connected device ecosystems.
Market share leadership reflects not only strength in traditional pacemakers and defibrillators, but also momentum in high-growth segments like pulsed field ablation (PFA) and 3D mapping systems.
Understanding the top global cardiac rhythm management companies can help stakeholders evaluate competitive positioning, portfolio depth, and future growth potential.
Find growth niches in minutes, not months.
Explore quick, actionable insights from the select markets.
Table of Contents
➜ BIOTRONIK – Cardiac Rhythm Management Global Footprint
➜ Abbott – Cardiac Rhythm Management and EP Market Strategy
➜ Johnson & Johnson – Biosense Webster Electrophysiology Leadership
➜ Boston Scientific – Cardiac Rhythm Management Market Position
➜ Medtronic – Cardiac Rhythm Management Market Share Analysis
➜ Emerging Competitors in the Cardiac Rhythm Management Market
Key Takeaways
- Market leadership increasingly reflects strength in electrophysiology (EP) and ablation, not only traditional pacing devices.
- Pulsed field ablation is reshaping competitive dynamics across the cardiac rhythm management market.
- Integrated portfolios spanning CRM devices and EP systems may support long-term share stability.
- Regional strengths continue to influence global competitive positioning.
#5: BIOTRONIK – Cardiac Rhythm Management Global Footprint
BIOTRONIK | BIOMONITOR IV™ Insertable Cardiac Monitor with Artificial Intelligence
BIOTRONIK ranked as the fifth-largest competitor globally in 2026.
The company holds notable pacemaker and ICD share in Western Europe and selected international markets. Its Home Monitoring connectivity platform and emphasis on long device life support customer loyalty.
BIOTRONIK also markets EP diagnostic and ablation catheters, and its BIOMONITOR IV™ integrates artificial intelligence-powered rhythm analysis.
Strengths may include:
- Strong presence in European pacing markets
- Reputation for device longevity and reliability
- Growing insertable cardiac monitor portfolio
Potential limitations may include:
- Smaller scale compared to the top three multinationals
- Limited influence in high-growth pulsed field ablation segments
BIOTRONIK’s integrated approach supports stable share in regions where European vendors are favored.
#4: Abbott – Cardiac Rhythm Management and EP Market Strategy
Abbott | AVEIR™ leadless pacemaker
Abbott ranked fourth globally in the CRM EP market in 2026, offering one of the most balanced portfolios across devices and EP technologies.
The AVEIR™ leadless pacemaker platform, including a dual-chamber configuration, supports atrial and ventricular coordination. Abbott also maintains full CRM device lines and implantable cardiac monitors (ICMs) with remote monitoring capabilities.
Its EnSite X™ mapping system and catheter portfolio position it as a major EP competitor. The company is advancing pulsed field ablation technologies to complement its radiofrequency systems.
Strengths may include:
- Broad, integrated CRM and EP offering
- Growing leadless pacemaker adoption
- Participation in nearly all major CRM EP tenders
Potential considerations may include:
- Intense competition in both mapping and ablation
- Dependence on successful scaling of PFA programs
Abbott’s cross-segment portfolio allows participation in both rhythm detection and interventional therapy.
👉 Learn more in the Global Cardiac Rhythm Management Market Report and Forecast to 2032.
Visit our Cardiovascular (❤️) Devices Market Insights page to learn more:
#3: Johnson & Johnson – Biosense Webster Electrophysiology Leadership
Johnson & Johnson | THERMOCOOL SMARTTOUCH® SF Catheter
Johnson & Johnson, operating through Biosense Webster, remains the leading electrophysiology company in the U.S. in 2026.
Its CARTO 3D mapping platform and THERMOCOOL SMARTTOUCH SF ablation catheter portfolio are widely used in atrial fibrillation workflows. The company holds dominant shares in 3D mapping systems and radiofrequency ablation.
It is also developing the VARIPULSE pulsed field ablation platform to compete in the fastest-growing ablation segment.
Strengths may include:
- Strongest position in EP mapping systems
- Broad installed base in electrophysiology labs
- Established RF ablation leadership
Potential constraints may include:
- Limited exposure to pacemakers, ICDs, and CRT devices
- Competitive pressure in pulsed field ablation from early movers
Despite limited involvement in traditional CRM devices, Biosense Webster’s EP dominance secures a strong competitive position across arrhythmia care.
#2: Boston Scientific – Cardiac Rhythm Management Market Position
Boston Scientific | FARAPULSE™ Pulsed Field Ablation System
Boston Scientific emerged second-largest competitor in the combined U.S. cardiac rhythm management, electrophysiology, and ablation market in 2026.
Its leadership is largely driven by strong performance in fast-growing EP and ablation segments, particularly with the FARAPULSE pulsed field ablation platform.
Following recent U.S. approvals, physician adoption accelerated rapidly, increasing penetration in atrial fibrillation procedures.
Strengths may include:
- Early momentum in pulsed field ablation
- Strong presence in EP labs
- Influence in high-growth procedure categories
Potential limitations may include:
- Smaller share in traditional pacemakers, ICDs, and CRT devices
- Greater exposure to competitive pressure in core CRM segments
Although not dominant in pacing, Boston Scientific’s influence across arrhythmia care has expanded due to its position in emerging technologies.
#1: Medtronic – Cardiac Rhythm Management Market Share Analysis
Medtronic | Arctic Front Advance Pro™ cardiac cryoablation catheter
Medtronic ranked as the overall share leader in the total U.S. CRM, EP, and ablation market in 2026.
The company maintains leadership in pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) systems. It also leads in MRI-compatible pacing and defibrillation technologies.
Its Arctic Front Advance Pro cryoballoon system remains a major player in cryoablation, supported by workflow-enhancing software.
Strengths may include:
- Deep hospital penetration and strong customer loyalty
- Leadership in core CRM device categories
- Established cryoballoon franchise
Potential challenges may include:
- Smaller role in 3D mapping and radiofrequency ablation compared to EP-focused competitors
- Exposure to slower growth in mature pacing segments
Medtronic’s scale and service network help secure stable total market share, even as energy-based ablation technologies evolve.
Emerging Competitors in the Cardiac Rhythm Management Market
Beyond the top five, several specialized companies are shaping niche and emerging segments:
- Kardium – Developing the Globe™ Pulsed Field System combining mapping and ablation in one platform.
- Adagio Medical – Advancing ultralow temperature cryoablation and pulsed field technologies.
- Lepu Medical and Apt Medical – Building strong regional positions in Asia.
- Imricor – Pioneering MR-guided EP lab systems.
- Pulse Biosciences – Expanding pulsed field ablation innovation.
These players show how innovation and regional strategies continue to influence the broader CRM EP landscape.
Global Cardiac Rhythm Management Companies Market Outlook
The competitive landscape in the global cardiac rhythm management market increasingly reflects a shift toward electrophysiology and energy-based ablation technologies.
Boston Scientific currently leads in overall combined share in the U.S., supported by pulsed field ablation momentum. Medtronic maintains strength in traditional CRM systems. Johnson & Johnson’s Biosense Webster dominates EP mapping. Abbott offers one of the most integrated portfolios. BIOTRONIK remains strong in European pacing markets.
As pulsed field ablation adoption expands and device ecosystems become more connected, companies may consider how portfolio breadth, regional presence, and innovation pipelines influence long-term positioning.
For deeper data, procedure volumes, competitive shares, and multi-year forecasts, detailed market analysis provides further clarity into where the global CRM market may be heading next.
Turn market painpoints into opportunities
Explore how procedure trends and competitor positioning create clear openings for industry experts in the market.
Related News
If you enjoyed this post, explore these insights next:
(POPULAR) Abbott and AtaCor Team Up on New ICD Technology
Is the Transcatheter Embolization Market Growing?
Fastest Growing Infusion Therapy Device Markets
How to Spot Growth Niches in the U.S. Peripheral Vascular Device Market in 2026
